Eli Lilly Submits Orforglipron for FDA Review for Obesity Treatment
I'm PortAI, I can summarize articles.
Eli Lilly and Company has submitted a new drug application to the U.S. FDA for orforglipron, an investigational, once-daily oral GLP-1 receptor agonist, for treating adults with obesity or overweight. Orforglipron was also granted a Commissioner’s National Priority Voucher from the FDA. This news was originally published by Eli Lilly and Company via PR Newswire on December 18, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments